Last reviewed · How we verify
hu14.18-Interleukin-2 fusion protein
hu14.18-Interleukin-2 fusion protein is a Biologic drug developed by Children's Oncology Group. It is currently in Phase 2 development. Also known as: IMMUNOCYTOKINE HU14.18-IL2 FUSION PROTEIN, humanized anti GD2 antibody fused with human IL-2, BB-IND-9798.
At a glance
| Generic name | hu14.18-Interleukin-2 fusion protein |
|---|---|
| Also known as | IMMUNOCYTOKINE HU14.18-IL2 FUSION PROTEIN, humanized anti GD2 antibody fused with human IL-2, BB-IND-9798 |
| Sponsor | Children's Oncology Group |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma (PHASE1, PHASE2)
- Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2 (PHASE1)
- Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma (PHASE2)
- Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma (PHASE2)
- Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma (PHASE2)
- hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma (PHASE2)
- Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hu14.18-Interleukin-2 fusion protein CI brief — competitive landscape report
- hu14.18-Interleukin-2 fusion protein updates RSS · CI watch RSS
- Children's Oncology Group portfolio CI
Frequently asked questions about hu14.18-Interleukin-2 fusion protein
What is hu14.18-Interleukin-2 fusion protein?
hu14.18-Interleukin-2 fusion protein is a Biologic drug developed by Children's Oncology Group.
Who makes hu14.18-Interleukin-2 fusion protein?
hu14.18-Interleukin-2 fusion protein is developed by Children's Oncology Group (see full Children's Oncology Group pipeline at /company/children-s-oncology-group).
Is hu14.18-Interleukin-2 fusion protein also known as anything else?
hu14.18-Interleukin-2 fusion protein is also known as IMMUNOCYTOKINE HU14.18-IL2 FUSION PROTEIN, humanized anti GD2 antibody fused with human IL-2, BB-IND-9798.
What development phase is hu14.18-Interleukin-2 fusion protein in?
hu14.18-Interleukin-2 fusion protein is in Phase 2.
Related
- Manufacturer: Children's Oncology Group — full pipeline
- Also known as: IMMUNOCYTOKINE HU14.18-IL2 FUSION PROTEIN, humanized anti GD2 antibody fused with human IL-2, BB-IND-9798
- Compare: hu14.18-Interleukin-2 fusion protein vs similar drugs
- Pricing: hu14.18-Interleukin-2 fusion protein cost, discount & access